Glucagon-like receptor agonists (GLP-1 RAs), a class of type 2 diabetes drug treatments, appear to also reduce the risk of colorectal cancer (CRC) researchers reported on Dec. 7, 2023 in JAMA Oncology. “Our results clearly demonstrate that GLP-1 RAs are significantly more effective than popular anti-diabetic drugs, such as Metformin or insulin, at preventing the development of CRC,” said co-lead […]
New research being presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 Oct) has identified a range of characteristics associated with a higher risk of sudden cardiac arrest in individuals with type 2 diabetes. These include the some commonly prescribed antibiotic and antipsychotic drugs, prokinetics (drugs used to treat gastrointestinal […]
UCLA-led research suggests that diabetes control can significantly improve for Latinos when a pharmacist implements an intervention that addresses these patients’ barriers to medication adherence. In this pharmacist-led intervention, pharmacists reviewed the patients’ lab results, vital signs, and barriers to adherence. They then used this information to design a personally-tailored intervention to boost medication adherence and optimize the treatment regimen. […]
GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now in the pipeline. IMI spoke to Hannah Beba, Consultant Pharmacist in Diabetes, Leeds Health and Care Partnership to find out more. [embedded content] GLP-1 agonists mimic the action of the naturally-occurring incretin […]
A simple blood test may predict the risk of progressive heart and kidney disease in people with Type 2 diabetes and kidney disease, according to new research published today in the American Heart Association’s flagship journal Circulation. “High levels of certain biomarkers are indicators of heart and kidney complications and may help predict future risk of disease progression,” said lead author James Januzzi, […]
AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adults with type-2 diabetes (T2D) as an adjunct to diet and exercise to improve glycaemic control. Xigduo XR combines two anti-hyperglycaemic agents with complementary mechanisms of action: dapagliflozin (trade name, Forxiga), a sodium-glucose cotransporter […]
Gestational diabetes (GDM) and overweight during pregnancy are associated with increased risk for type 2 diabetes. Although postpartum weight loss can reduce diabetes risk, effective interventions are lacking – especially for Latina populations, who experience higher than average rates of GDM, overweight and chronic diabetes. In an effort to address this evidence gap, researchers from the University of California, San […]
Persons with Type 2 diabetes have achieved complete remission of disease following use of an intermittent fasting diet intervention, researchers reported on Dec. 22, 2022 in the Journal of Clinical Endocrinology & Metabolism. Complete diabetes remission is defined as an HbA1c of less than 6.5% at least one year after stopping diabetes medication. “Type 2 diabetes is not necessarily a […]
After an intermittent fasting diet intervention, patients achieved complete diabetes remission, defined as an HbA1c (average blood sugar) level of less than 6.5% at least one year after stopping diabetes medication, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Intermittent fasting diets have become popular in recent years as an effective weight loss […]
A low-carb diet enables persons at risk of Type 2 diabetes to lower their blood sugar before the onset of that disease, researchers reported on Oct.26, 2022 in JAMA Network Open “We already know that a low-carbohydrate diet is one dietary approach used among people who have Type 2 diabetes, but there is not as much evidence on effects of […]
Recent Comments